E156 Micro-Paper · Africa Clinical Trials

Colonial Legacy in Sponsorship

Former colonial powers remain disproportionately represented as sponsors in thei...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
No data
Trial Flow Global Africa Africa US Europe Egypt South Af Uganda
Colonial Legacy in Sponsorship by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Phase Distribution Africa US Europe Phase 1 11 127.7 45.0 Phase 2 20 142.1 138.5 Phase 3 52 515.9 179.6 Phase 4 12 117.5 117.3 515.9 11
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Research Profile Volume Growth Phase3 Complete Diversity
No data
Enrollment Distribution Africa Reference 5000 10000 15000 20000
Why It Matters

Former colonial powers remain disproportionately represented as sponsors in their former colonies — France in Francophone Africa, UK in Anglophone Africa — perpetuating dependency structures.

In the governance and sovereignty of African clinical trials, does the pattern of colonial legacy in sponsorship reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. The Herfindahl-Hirschman index reached 3472.872, exceeding the threshold of 0.25 that indicates a highly concentrated distribution. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Question

In the governance and sovereignty of African clinical trials, does the pattern of colonial legacy in sponsorship reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

The Herfindahl-Hirschman index reached 3472.

Boundary

872, exceeding the threshold of 0.

Extra

25 that indicates a highly concentrated distribution.

Extra

These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.

Extra

Interpretation is limited by the use of a single registry and the absence of non-English trial databases.